Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation
The first use of daratumumab in desensitization demonstrated infusion-related adverse (AEs) events and rapid, albeit transient, reductions in anti-HLA antibodies, with less than 40% of durable responders, limiting its potential clinical use.
Authors
- José L. Cohen (ORCID: https://orcid.org/0000-0002-5077-6726)
- Florence Canouï‐Poitrine (ORCID: https://orcid.org/0000-0001-9970-6051)
- Cédric Usureau (ORCID: https://orcid.org/0009-0002-4366-7211)
- Allan Thiolat
- Caroline Pilon (ORCID: https://orcid.org/0000-0003-2850-6591)
- Anna Boueilh
- Philippe Grimbert (ORCID: https://orcid.org/0000-0001-7490-561X)
- Emmanuelle Boutin
- Marie Matignon
- Vissal David Kheav
- Nizar Joher (ORCID: https://orcid.org/0000-0002-4865-4834)
- Jean‐Luc Taupin
- Maryvonnick Carmagnat
Institutions
- Inserm (FR)
- Université Paris-Est Créteil (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Hôpital Saint-Louis (FR)
- Hôpital Albert-Chenevier (FR)
- Institut Mondor de Recherche Biomédicale (FR)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1016/j.ekir.2024.08.020
- Citations
- 13
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 5.82
Funders
- Assistance Publique - Hôpitaux de Paris
- Assistance publique-Hôpitaux de Paris
- Janssen Pharmaceuticals